Revenue and Growth - Revenue for the six months ended June 30, 2021, was approximately RMB 915 million, a significant increase of 55.8% compared to RMB 587 million for the same period in 2020[11]. - Revenue from medical beauty services was approximately RMB 892 million, representing a growth of about 55.2% from RMB 575 million in the previous year[25]. - Revenue from skin beauty services and minimally invasive beauty services increased by approximately 122.1% and 71.1%, reaching RMB 409 million and RMB 345 million respectively[27]. - For the six months ended June 30, 2021, total revenue from medical beauty services was RMB 89,194,000, and from consulting services was RMB 2,298,000, totaling RMB 91,492,000, representing an increase from RMB 58,730,000 in the same period of 2020[98]. - The total revenue for the period was approximately RMB 915 million, a significant increase of 55.8% compared to RMB 587 million for the same period in 2020[25]. Customer Metrics - Active customer count increased to 43,325, up 39.4% from 31,080 in the first half of 2020[12]. - Average spending per active customer rose to approximately RMB 2,059, an increase of about 11.4% from RMB 1,849 in the first half of 2020[12]. - New customer count reached 16,130, representing a growth of 15.8% compared to 13,928 in the first half of 2020[12]. - Repeat customer count increased to 27,195, a growth of 58.6% from 17,152 in the same period of 2020[12]. Financial Performance - The net loss for the period was approximately RMB 54 million, a reduction of about 53.8% from RMB 118 million in the same period of 2020[11]. - The gross profit for the period was approximately RMB 371 million, an increase of about 52.7% compared to RMB 243 million for the same period in 2020[30]. - The gross margin was approximately 40.5%, a decrease of about 0.9 percentage points from 41.4% in the previous year[30]. - The company recorded a loss of approximately RMB 5.4 million for the period, compared to a loss of RMB 11.8 million for the six months ended June 30, 2020[34]. - The company reported a pre-tax loss of RMB 5,549 thousand for the six months ended June 30, 2021, an improvement from a loss of RMB 12,352 thousand in the same period of 2020[90]. Expenses and Liabilities - The sales cost for the period was approximately RMB 544 million, an increase of about 57.9% from RMB 344 million in the previous year[28]. - Sales and distribution expenses were approximately RMB 25.2 million, an increase of about RMB 10.1 million from RMB 15.1 million for the six months ended June 30, 2020[34]. - Administrative expenses decreased to approximately RMB 16.6 million from RMB 20.3 million for the six months ended June 30, 2020, a reduction of about RMB 3.7 million[34]. - The total liabilities as of June 30, 2021, were approximately RMB 80.6 million, down from RMB 85.6 million as of December 31, 2020[38]. - The debt-to-equity ratio was 42.4% as of June 30, 2021, compared to 45.8% as of December 31, 2020[38]. Investments and Expansion - The company plans to complete an expansion of approximately 1,500 square meters at Wuhu Raily Medical Aesthetic Clinic, increasing total building area by about 106.8%[12]. - The company invested RMB 3.5 million to acquire a 25% stake in Bioris Medical (Beijing) Trading Co., Ltd. as part of its strategy to vertically expand its supply chain[12]. - The company is expanding its medical beauty facilities, increasing the total area from approximately 7,972 square meters to about 12,672 square meters, a growth of 59.0%[17]. - The company is implementing renovation and expansion plans for its medical beauty institutions to improve service capacity and customer experience[17]. - The company has committed to strategic acquisitions, allocating HKD 12.2 million (15.0%) of the net proceeds for this purpose by December 31, 2023[50]. Shareholder Information - As of June 30, 2021, Mr. Fu Haishu holds 1,109,283,463 shares, representing 53.10% of the company's equity[57]. - Major shareholder 瑞德咨询管理有限公司 holds 1,109,283,463 shares, representing 53.10% of the company's equity[62]. - The total number of shares issued by the company as of June 30, 2021, is 2,089,040,000 shares[64]. - The company did not declare any interim dividends for the six months ending June 30, 2020[64]. Compliance and Governance - The company has adopted the standard code of conduct for directors' securities transactions as per the listing rules[64]. - The company confirmed compliance with the standard code during the reporting period[64]. - The audit committee has reviewed and approved the interim financial information, ensuring compliance with relevant regulations and standards[76]. Cash Flow and Assets - The net cash used in operating activities for the six months ended June 30, 2021, was RMB (15,815) thousand, compared to RMB (9,238) thousand for the same period in 2020, indicating a worsening cash flow situation[90]. - Cash and cash equivalents at the end of the period were RMB 103,633,000, a significant increase from RMB 27,499,000 at the end of the previous year[92]. - The company’s cash and bank balances decreased from RMB 158,898 thousand as of December 31, 2020, to RMB 146,916 thousand as of June 30, 2021, a decline of about 7.5%[84]. - The company’s inventory increased from RMB 11,621 thousand as of December 31, 2020, to RMB 15,130 thousand as of June 30, 2021, representing an increase of approximately 29.0%[84]. - The total assets increased to RMB 140,935 thousand as of June 30, 2021, compared to RMB 137,651 thousand at the end of 2020[101].
瑞丽医美(02135) - 2021 - 中期财报